We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+6.52%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$517M
AUM Growth
+$19.8M
Cap. Flow
-$2.75M
Cap. Flow %
-0.53%
Top 10 Hldgs %
81.3%
Holding
59
New
10
Increased
8
Reduced
9
Closed
13

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$8.15M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$5.53M
3
CLDX icon
Celldex Therapeutics
CLDX
+$2.84M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$2.56M
5
SLNO
Soleno Therapeutics
SLNO
+$2.27M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$16.5M
2
ARGX icon
argenx
ARGX
+$7.31M
3
CYTK icon
Cytokinetics
CYTK
+$6.28M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$4.34M
5
INSM icon
Insmed
INSM
+$2.51M

Sector Composition

Rank Sector Weight
1 Healthcare 75.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
26
Apogee Therapeutics
APGE
$10.1B
$2.3M 0.44%
58,400
-3,190
-5% -$155K
SWTX
27
DELISTED
SpringWorks Therapeutics
SWTX
$2.03M 0.39%
53,930
– –
IDYA icon
28
IDEAYA Biosciences
IDYA
$3.42B
$1.91M 0.37%
54,392
+1,900
+4% +$75.2K
VRNA
29
DELISTED
Verona Pharma
VRNA
$1.89M 0.37%
130,790
– –
XENE icon
30
Xenon Pharmaceuticals
XENE
$6.06B
$1.56M 0.3%
40,000
– –
MREO
31
Mereo BioPharma
MREO
$54.7M
$1.52M 0.29%
421,359
– –
CRL icon
32
Charles River Laboratories
CRL
$11.2B
$1.43M 0.28%
6,905
– –
KURA icon
33
Kura Oncology
KURA
$800M
$1.18M 0.23%
57,178
+17,700
+45% +$364K
NAMS icon
34
NewAmsterdam Pharma
NAMS
$3.25B
$1.04M 0.2%
54,285
– –
ASND icon
35
Ascendis Pharma A/S
ASND
$16B
$1.01M 0.2%
7,440
-8,454
-53% -$1.15M
SLN
36
Silence Therapeutics
SLN
$495M
$997K 0.19%
52,476
– –
SNDX icon
37
Syndax Pharmaceuticals
SNDX
$1.69B
$991K 0.19%
+48,263
New +$1.01M
KROS icon
38
Keros Therapeutics
KROS
$199M
$914K 0.18%
+20,000
New +$1.07M
CRBP icon
39
Corbus Pharmaceuticals
CRBP
$166M
$905K 0.17%
+20,000
New +$841K
EYPT icon
40
EyePoint Inc
EYPT
$1.03B
$883K 0.17%
101,500
+50,000
+97% +$698K
ANNX icon
41
Annexon
ANNX
$834M
$723K 0.14%
147,485
– –
LRMR icon
42
Larimar Therapeutics
LRMR
$397M
$656K 0.13%
90,490
+32,300
+56% +$247K
IRON icon
43
Disc Medicine
IRON
$2.94B
$606K 0.12%
13,440
-73,600
-85% -$2.5M
PLRX icon
44
Pliant Therapeutics
PLRX
$64.4M
$538K 0.1%
50,000
-50,000
-50% -$645K
MDGL icon
45
Madrigal Pharmaceuticals
MDGL
$10.8B
$436K 0.08%
1,557
– –
SRPT icon
46
Sarepta Therapeutics
SRPT
$1.57B
$411K 0.08%
+2,600
New +$334K
ABBV icon
47
AbbVie
ABBV
$443B
– –
-90,821
Closed -$16.5M
ARVN icon
48
Arvinas
ARVN
$518M
– –
-40,000
Closed -$1.65M
BMEA icon
49
Biomea Fusion
BMEA
$84.6M
– –
-35,452
Closed -$530K
CYTK icon
50
Cytokinetics
CYTK
$10.5B
– –
-89,525
Closed -$6.28M
1
2
3

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $498M AUM 20.41% 1-Year Est. Return

Artia Global Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Artia Global Partners held 59 positions worth $517M, up 4% from $498M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Artia Global Partners's Q2 2024 filing shows 10 new, 8 increased, 9 reduced and 13 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 35,000 shares worth $8.51M. The largest sale was AbbVie, an estimated $16.5M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 82% a quarter earlier.

  • Artia Global Partners's largest Q2 2024 buy was Alnylam Pharmaceuticals: 35,000 shares worth $8.51M.
  • Artia Global Partners added most to Merck in Q2 2024, an estimated $8.15M increase.
  • Artia Global Partners's biggest Q2 2024 reduction was argenx, cutting an estimated $7.31M.
  • Artia Global Partners fully exited AbbVie in Q2 2024, selling an estimated $16.5M.
  • Artia Global Partners's ten largest holdings make up 81% of its $517M portfolio in Q2 2024.
  • Artia Global Partners opened 10 new positions and closed 13 in Q2 2024.
  • Artia Global Partners's portfolio value rose 4% quarter-over-quarter to $517M.

Based on Artia Global Partners's 13F filing for Q2 2024, filed 14 Aug 2024.